Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomised, Multicentre, Pragmatic Trial Comparing a Single-Dose vs. Twice Yearly Zoledronate in Patients With Early Stage Breast Cancer (REaCT-ZOL)

NCT03664687 is registered in ClinicalTrials.gov with Ottawa Hospital Research Institute as lead sponsor.

NCT NCT03664687
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03664687 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomised, Multicentre, Pragmatic Trial Comparing a Single-Dose vs. Twice Yearly Zoledronate in Patients With Early Stage Breast Cancer (REaCT-ZOL)
Lead sponsor
Ottawa Hospital Research Institute
Phase
Phase 4
Overall status
Completed
Start date
October 31, 2018
Completion date
March 28, 2025
Enrollment
211 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

early-stage breast cancer